FGFR2 and cholangiocarcinoma: Very recently, FDA granted the accelerated approval to Infigratinib for adults with previously treated, unresectable locally advanced or metastatic CCA with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement [36].